XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business combination - Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
9 Months Ended
Jun. 01, 2016
Sep. 30, 2017
Dec. 31, 2016
[1]
Amounts Recognized      
Goodwill   $ 155,593 $ 155,593
Licensed IP      
Amounts Recognized      
Weighted average useful life   12 years 6 months  
ARIAD Pharmaceuticals      
Amounts Recognized      
Current assets   $ 21,363  
Property and equipment   850  
Restricted cash   432  
Intangible assets   283,000  
Total identifiable assets   305,645  
Current liabilities   (15,538)  
Other long term liabilities   (5,226)  
Total liabilities assumed   (20,764)  
Goodwill   155,593  
Total fair value of consideration transferred   $ 440,474  
ARIAD Pharmaceuticals | Maximum      
Amounts Recognized      
Development costs $ 7,000    
ARIAD Pharmaceuticals | Licensed IP      
Amounts Recognized      
Discount rate (as a percent) 15.00%    
Gross margins (as a percent) 98.00%    
Weighted average useful life 12 years 6 months    
ARIAD Pharmaceuticals | Licensed IP | Minimum      
Amounts Recognized      
Tax rates (as a percent) 7.80%    
ARIAD Pharmaceuticals | Licensed IP | Maximum      
Amounts Recognized      
Tax rates (as a percent) 13.80%    
Development costs $ 7,000    
ARIAD Pharmaceuticals | IPR&D      
Amounts Recognized      
Probability of technical success (“PTS”) (as a percent) 25.00%    
Discount rate (as a percent) 16.00%    
Gross margins (as a percent) 98.00%    
ARIAD Pharmaceuticals | IPR&D | Minimum      
Amounts Recognized      
Tax rates (as a percent) 7.80%    
ARIAD Pharmaceuticals | IPR&D | Maximum      
Amounts Recognized      
Tax rates (as a percent) 13.80%    
[1] The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements at that date.